PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
Synapse
⌘+K
Synapse
March 22, 2024Cancer Research

Abstract 5761: A nanoplatform based on an in situ tumor vaccine and activation of STING and TLR7/8 pathways for enhanced NSCLC immunotherapy

View Full Paper
Ask AI
Bookmark
Share

Authors

HZHaiyu ZhouHHHengliang HouBXBin Xu

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Zhou et al. (2024) studied this question.

synapsesocial.com/papers/68e72e24b6db6435876a77f1https://doi.org/10.1158/1538-7445.am2024-5761
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Effect of NIR-II on cancer nanocomposite vaccines for lymph node targeted delivery and enhanced immunotherapy.2024
  2. 2A Versatile Polymer‐Based In Situ Nanovaccine to Boost Cancer Immunotherapy2026
  3. 3Abstract 481: Proteomimetic polymers limit tumor growth in multiple models via potent antigen-specific T cell activation2024
  4. 4Abstract 1551: Intratumoral biodegradable nanofluidic platform for localized multimodal immunotherapy enhances tumor eradication and immune memory2026
  5. 5Programming of in Situ Tumor Vaccines via Supramolecular Nanodrug/Hydrogel Composite and Deformable Nanoadjuvant for Cancer Immunotherapy2024 · 18 citations